Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on November 24, 2017, to report the unregistered sale of equity securities. The company is incorporated in Delaware and maintains its principal executive offices in Tucker, Georgia.
Key Financial Metrics
The filing details a specific financing transaction rather than periodic financial performance metrics.
- Capital Raised: $1,000,000 aggregate principal amount.
- Instrument: 8% Convertible Notes due November 24, 2019.
- Conversion Price: $0.27 per share (subject to adjustment).
- Investors: Two accredited investors, including the Company's Chairman of the Board.
- Use of Proceeds: Working capital and general corporate purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels outside of this new issuance.
Material Changes
The primary material change is the issuance of $1,000,000 in convertible debt. This transaction increases the company's liabilities and potential future equity dilution. The Notes were issued under Section 4(a)(2) of the Securities Act of 1933 and Rule 506, with no general solicitation.
Guidance, Outlook, and Risks
Management Commentary: The company intends to utilize the net proceeds for working capital and general corporate purposes.
Contingencies and Terms:
- Automatic Conversion: Notes automatically convert upon a "Qualified Financing" or a change of control/sale of substantially all assets.
- Conversion Price Adjustment: Upon a Qualified Financing, the conversion price becomes the lesser of $0.27 per share or the price per share of the securities sold in that financing.
- Restrictions: The Notes and underlying shares cannot be offered or sold in the U.S. without an effective registration statement or exemption.
The filing does not provide specific forward-looking guidance, risk factors, or unusual items beyond the terms of the note issuance.
Investor Verification Checklist
- Verify the total outstanding debt and equity dilution resulting from this $1,000,000 issuance.
- Confirm the definition of "Qualified Financing" in the attached Securities Purchase Agreement to understand conversion triggers.
- Assess the company's current cash runway and burn rate to determine if the proceeds are sufficient for stated working capital needs.
- Review the relationship and potential conflicts of interest regarding the Chairman of the Board as an investor.